Inclusion Criteria:

          -  Provide a signed and dated informed consent form prior to initiation of study-specific
             procedures.

          -  Patients with the indicated advanced or metastatic solid tumor as follows:

               1. Microsatellite-stable colorectal cancer (MSS-CRC) who are currently receiving
                  systemic treatment with a fluoropyrimidine and oxaliplatin and/or irinotecan that
                  may include a VEGF or EGFR targeting therapy as their 1L therapy for metastatic
                  disease OR who have experienced disease progression following treatment with a
                  fluoropyrimidine, oxaliplatin, and irinotecan that may include a VEGF or EGFR
                  targeting therapy and have not received additional lines of systemic therapy in
                  the metastatic setting.

               2. Non-small cell lung cancer (NSCLC) who are currently receiving systemic treatment
                  with an anti-PD-(L)1 antibody in combination with cytotoxic, platinum-based
                  chemotherapy OR who have experienced disease progression following treatment with
                  an anti-PD-(L)1 antibody in combination with cytotoxic, platinum-based
                  chemotherapy (or anti-PD-(L)1 alone if patient refuses platinum-based
                  chemotherapy), and have not received additional lines of systemic therapy in the
                  metastatic setting.

               3. Pancreatic ductal adenocarcinoma (PDA) who are currently receiving systemic
                  cytotoxic chemotherapy as their 1L therapy for metastatic disease OR who have
                  experienced disease progression on 1L systemic cytotoxic chemotherapy and have
                  received no more than 1 prior line of therapy in the metastatic setting.

               4. Any solid tumor histology where the patient has experienced disease progression
                  with all available therapies known to confer clinical benefit

          -  Patient's tumor possesses one of the mutations listed below, and is determined to
             express a HLA allele for antigen presentation of the identified tumor mutation:

        BRAF_G466V // CTNNB1_S37F // CTNNB1_S45F // CTNNB1_S45P // CTNNB1_T41A //
        ERBB2_Y772_A775dup // KRAS_G12C or NRAS_G12C // KRAS_G12D or NRAS_G12D // KRAS_G12V //
        KRAS_G13D // KRAS_Q61H or NRAS_Q61H // KRAS_Q61K or NRAS_Q61K // KRAS_Q61L or NRAS_Q61L //
        KRAS_Q61R or NRAS_Q61R // TP53_K132E // TP53_K132N // TP53_R213L // TP53_R249M //
        TP53_S127Y

          -  ECOG Performance Status 0 or 1

          -  Measurable disease according to RECIST v1.1

          -  Adequate organ function, as measured by laboratory values (criteria listed in
             protocol)

        Exclusion Criteria:

          -  Tumors with genetic characteristics as follows:

               1. For NSCLC, patients with a known genetic driver alteration in EGFR, ALK, ROS1,
                  RET, or TRK

               2. Patients with known MSI-high disease based on institutional standard

          -  Known exposure to chimpanzee adenovirus or any history of anaphylaxis in reaction to a
             vaccination

          -  Bleeding disorder (eg., factor deficiency, coagulopathy) or history of significant
             bruising or bleeding following IM injections or blood draws

          -  History of allogenic/solid organ transplant

          -  Active, known, or suspected autoimmune disease

          -  Active tuberculosis or recent (<2 week) clinically significant infection, or evidence
             of active hepatitis B or hepatitis C

          -  Known history of positive test for human immunodeficiency (HIV) or known acquired
             immunodeficiency syndrome (AIDS)

        Complete inclusion and exclusion criteria are listed in the clinical study protocol.